Acute Myelogenous Leukemia (AML) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

FDA lifts second trial hold for Prescient's lead drug, with one to go - FierceBiotech



FierceBiotech
 
FDA lifts second trial hold for Prescient's lead drug, with one to go 
FierceBiotech
... Prescient's PTX-200 candidate on hold in May after a subject enrolled in the company's breast cancer study developed liver failure and died, bringing three trials of the Akt inhibitor in breast and ovarian cancer and acute myeloid leukemia (AML) to ...

 


Crowd control | Nature Reviews Cancer - Nature.com



Crowd control | Nature Reviews Cancer 
Nature.com
In acute myeloid leukaemia (AML), accumulating leukaemic blasts occupy specialized niches in the bone marrow (BM). However, the extent to which normal ...

and more » 


Acute Myeloid Leukemia Market Therapeutics Assessment 2017 to 2025 - Research of Market



Acute Myeloid Leukemia Market Therapeutics Assessment 2017 to 2025 
Research of Market
Acute Myeloid Leukemia (AML)-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Acute Myeloid Leukemia (AML). The report provides a complete understanding of the ...

and more » 


Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia - Targeted Oncology



Targeted Oncology
 
Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia 
Targeted Oncology
Although now an established treatment modality for CD19+ lymphoid malignancies, the development of CAR T-cell strategies for myeloid malignancies, specifically acute myeloid leukemia (AML), is still being explored preclinically and in phase I trials.
Blocking key pathways is a way to defeat cancer stem cells Medical Xpress

all 3 news articles » 


Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid ... - GlobeNewswire (press release)



Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid ... 
GlobeNewswire (press release)
... today announced updated data from the fifth dose cohort of OX1222, a phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).

and more » 


Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American ... - Business Wire (press release)



Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American ... 
Business Wire (press release)
In acute myeloid leukemia (AML), new data for investigational uses of IDHIFAŽ (enasidenib) in patients in the relapsed/refractory and front-line settings in combinations, as well as new phase II data for CC486 in post-transplant maintenance for AML and ...

and more » 


MEI Pharma to Host Annual Meeting of Stockholders - GuruFocus.com



MEI Pharma to Host Annual Meeting of Stockholders 
GuruFocus.com
Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive ...

and more » 


The Leukemia & Lymphoma Society Funds $46 M In New Research - Pharmaceutical Processing



Pharmaceutical Processing
 
The Leukemia & Lymphoma Society Funds $46 M In New Research 
Pharmaceutical Processing
The Leukemia & Lymphoma Society (LLS) Funds $46 Million in New Research to Find Cures.

and more » 


Millville woman leaves $60500 for cancer research, patients - Vineland Daily Journal



Vineland Daily Journal
 
Millville woman leaves $60500 for cancer research, patients 
Vineland Daily Journal
The money, Calcagni said, will go into the society's ongoing campaign to raise money for research into acute myeloid leukemia (AML) and to pay for patient access to treatment. Riggins made the bequest personal, arranging it in specific memory of Ronald K.

 


Four new treatments for acute myeloid leukemia to watch - ModernMedicine



Four new treatments for acute myeloid leukemia to watch 
ModernMedicine
There are four new treatments for acute myeloid leukemia (AML) that have recently been approved by the FDA. That's a huge breakthrough, considering that there were no new drug approvals between 2000 and 2017?and there wasn't a ...